Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.63 |
| ▸ | CA2 | P00918 | 4/20 | 0.63 |
| ▸ | CA4 | P22748 | 4/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495202 | 0.93 | CA2 (0.57) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL4287508 | 0.92 | CA1 (0.56) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL3492288 | 0.90 | CA1 (0.54) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL3493063 | 0.89 | CA1 (0.61) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL2753820 | 0.89 | CA1 (0.64) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL5539406 | 0.89 | CA1 (0.61) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL5539410 | 0.89 | CA1 (0.61) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL28429512 | 0.88 | SIGMAR1 (0.54) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL28429511 | 0.88 | SIGMAR1 (0.54) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL3496353 | 0.88 | SIGMAR1 (0.54) | CA1CA2CA4CA9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CA1 2606/4885CA2 1023/4885CA4 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.